Abstract
The number of patients suffering from Mycobacterium abscessus complex (MABC) pulmonary diseases is steadily increasing. MABC consists of three subspecies, and it is recommended that the three subspecies be distinguished because of their differing macrolide susceptibilities. Unfortunately, current methods are inefficient due to their high cost, complexity, and time requirements. The third-generation Bruker MALDI Biotyper (MBT) Sirius has the capability to detect phospholipids and glycolipids using negative-ion mode. Mycobacterial cell walls are rich in lipids, and if lipid structure diversity can serve as species-specific fingerprints, this method may provide an alternative for microbial identification. This study aimed to examine the accuracy of discriminating between the three MABC subspecies by lipid profiling. Our best model failed to differentiate the three subspecies. Even in the two-dimensional space of the most significant peaks, M. abscessus and M. massiliense could not be separated. The agreement rate between lipid fingerprint-based and WGS-based identification was, at most, 47.2% for negative-ion mode. Even after applying recent machine learning algorithms to detect variables and create predictive models, accuracy remained at 50%. Our results suggest that using lipid fingerprinting alone to differentiate the three MABC subspecies is currently inadequate. Further advancements and standardization of MALDI-TOF MS-based methods are necessary for the routine differentiation of MABC subspecies in clinical settings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was in part supported in part by grants from the Japan Agency for Medical Research and Development (AMED) to MY (JP24wm0225022 and JP24fk0108714) and to YH (JP23fk0108608, JP24fk0108673, JP24gm1610003, JP24gm1610007, JP24wm0125007, JP24wm0225022, JP24wm0325054, and JP24fk0108701). This study was also supported in part by grants from the Japan Society for the Promotion of Science (JSPS) for International Collaborative Research to YH and MY (JP63KK0138), and for Scientific Research (A) to YH (JP24H00331), and for Scientific Research (C) to MY and YH (JP23K07665 and JP23K07958).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The National Institute of Infectious Diseases medical research ethics committee reviewed and approved this study, which included human subjects (#1004 and #1005 for the Japanese and Taiwanese, respectively).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors. All raw read data for sequenced strains in this study were deposited in the DNA Data Bank of Japan (DDBJ) and mirrored at the National Center for Biotechnology Information (NCBI) under BioProject accession number PRJDB10333.
